NUCLEAR RECEPTOR BINDING AGENTS Russian patent published in 2016 - IPC A61K31/47 A61P3/04 

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, namely, to gastrology and endocrinology, and can be used for prevention, treatment, delay of the onset, reduction of the incidence or reduction of the severity of a condition associated with high fat diet consumption, fatty liver infiltration, post-menopausal obesity, to increase energy consumption in a patient, to increase lean body mass. For this purpose, the patient in need thereof, administering a therapeutically effective amount of an estrogen receptor ligand compound, wherein the compound represents 4-bromo-6,8-dihydroxy-2-(4-hydroxyphenyl)isoquinoline-1-(2H)-on (12u) or 4-cyano-6,8-dihydroxy-2-(4-hydroxyphenyl)isoquinoline-1-(2H)-on (14m).

EFFECT: group of inventions provides increase in treatment efficacy of said states within its safety.

13 cl, 10 tbl, 33 dwg, 41 ex